Longeveron Inc. Announces Key Leadership Appointment and Clinical Trial Milestones
MIAMI, June 26, 2025 — Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company specializing in cellular therapies for aging-related and life-threatening conditions, has announced the appointment of Than Powell as Chief Business Officer, effective July 7, 2025. This strategic move is aimed at bolstering the company’s business strategy, particularly in its Alzheimer’s disease program and international efforts for its hypoplastic left heart syndrome (HLHS) program.
Than Powell, who brings over 25 years of experience in the pharmaceutical and biotech sectors from companies such as GSK and Eli Lilly, will oversee Longeveron’s partnering and international strategy efforts. “We are delighted to have Than join Longeveron at this transformational time in the Company’s development,” said Wa’el Hashad, Chief Executive Officer at Longeveron. “His expertise will be invaluable as we advance our strategic initiatives.”
In parallel with this leadership change, Longeveron has achieved significant progress in its clinical trials. The company recently completed enrollment in its pivotal Phase 2b clinical trial evaluating Laromestrocel as a treatment for hypoplastic left heart syndrome (HLHS). The trial’s top-line results are anticipated in the third quarter of 2026, following the final follow-up at 12 months. If the results are positive, Longeveron plans to submit a Biological License Application (BLA) for full traditional approval for HLHS in 2026.
The HLHS program has been recognized by the U.S. FDA with Rare Pediatric Disease designation, Orphan drug designation, and Fast track designation, highlighting its potential to address unmet medical needs. The U.S. market potential for this program is estimated to be up to $1 billion.
Longeveron, based in Miami, Florida, continues to focus on developing innovative cellular therapies to address critical health challenges. The company’s recent achievements and strategic appointments underscore its commitment to advancing regenerative medicine and improving patient outcomes globally.
For more information about Longeveron Inc., visit their website at www.longeveron.com or explore stock trading possibilities on the Nasdaq exchange.
Company Overview: Longeveron Inc.
- Sector: Health Care
- Primary Exchange: Nasdaq
- Currency: USD
- Close Price (2025-06-24): $1.27
- 52 Weeks High (2024-07-09): $6.40
- 52 Weeks Low (2025-06-03): $1.14
- Market Cap: $18,160,000 USD
- Price Earnings Ratio: -0.432602
Longeveron Inc. is a clinical-stage biotechnology company focused on developing cellular therapies for aging-related and life-threatening conditions. The company serves a global customer base and is headquartered in Miami, Florida.